A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2018
Price : $35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 05 Sep 2018 Primary endpoint has been met. (Percent change in EASI score)
- 05 Sep 2018 Results published in the Journal of Allergy and Clinical Immunology.
- 21 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.